Literature DB >> 26925665

Differential Expression of O-glycoprotein Glycans in Cholangiocarcinoma Cell Lines.

Krajang Talabnin1, Chutima Talabnin, Mayumi Ishihara, Parastoo Azadi, Sopit Wongkham, Banchob Sripa.   

Abstract

Protein glycosylation is the most common posttranslational modification in mammalian cells. Aberrant protein glycosylation has been reported in various diseases, including cancer. We identified and quantified the glycan structures of O-linked glycoprotein from cholangiocarcinoma (CCA) cell lines from different histological types and compared their profiles by nanospray ionization-linear ion trap mass spectrometry (NSI-MSn). Five human CCA cell lines, K100, M055, M139, M213 and M214 were characterized. The results showed that the O-linked glycans of the CCA cell lines comprised tri- to hexa-saccharides with terminal galactose and sialic acids: NeuAc1Gal1GalNAc1, Gal2GlcNAc1GalNAc1, NeuAc2Gal1GalNAc1 NeuAc1Gal2GlcNAc1GalNAc1 and NeuAc2Gal2GlcNAc1GalNAc1 All five CCA cell lines showed a similar glycan pattern, but with differences in their quantities. NeuAc1Gal1GalNAc1 proved to be the most abundant structure in poorly differentiated adenocarcinoma (K100; 57.1%), moderately differentiated adenocarcinoma (M055; 42.6%) and squamous cell carcinoma (M139; 43.0%), while moderately to poorly differentiated adenocarcinoma (M214; 40.1%) and adenosquamous cell carcinoma (M213; 34.7%) appeared dominated by NeuAc2Gal1GalNAc1. These results demonstrate differential expression of the O-linked glycans in the different histological types of CCA. All five CCA cell lines have abundant terminal sialic acid (NeuAc) O-linked glycans, suggesting an important role for sialic acid in cancer cells. Our structural analyses of glycans may provide important information regarding physiology of disease-related glycoproteins in CCA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26925665      PMCID: PMC4809418          DOI: 10.7314/apjcp.2016.17.2.691

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  19 in total

Review 1.  On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database.

Authors:  R Apweiler; H Hermjakob; N Sharon
Journal:  Biochim Biophys Acta       Date:  1999-12-06

2.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

3.  A comprehensive procedure for preparation of partially methylated alditol acetates from glycoprotein carbohydrates.

Authors:  K R Anumula; P B Taylor
Journal:  Anal Biochem       Date:  1992-05-15       Impact factor: 3.365

4.  Protein glycosylation: new challenges and opportunities.

Authors:  Chi-Huey Wong
Journal:  J Org Chem       Date:  2005-05-27       Impact factor: 4.354

5.  An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas.

Authors:  J Burchell; R Poulsom; A Hanby; C Whitehouse; L Cooper; H Clausen; D Miles; J Taylor-Papadimitriou
Journal:  Glycobiology       Date:  1999-12       Impact factor: 4.313

6.  A novel carbohydrate antigen expression during development of Opisthorchis viverrini- associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis.

Authors:  Kanlayanee Sawanyawisuth; Atit Silsirivanit; Kunlathida Kunlabut; Nattawat Tantapotinan; Kulthida Vaeteewoottacharn; Sopit Wongkham
Journal:  Parasitol Int       Date:  2011-07-20       Impact factor: 2.230

7.  Aberrant glycosylation in cholangiocarcinoma demonstrated by lectin-histochemistry.

Authors:  Somsiri Indramanee; Atit Silsirivanit; Chawalit Pairojkul; Chaisiri Wongkham; Sopit Wongkham
Journal:  Asian Pac J Cancer Prev       Date:  2012

8.  Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma.

Authors:  Chatchai Phoomak; Atit Silsirivanit; Chaisiri Wongkham; Banchob Sripa; Anucha Puapairoj; Sopit Wongkham
Journal:  Asian Pac J Cancer Prev       Date:  2012

9.  Comprehensive glycomics comparison between colon cancer cell cultures and tumours: implications for biomarker studies.

Authors:  Jenny H L Chik; Jerry Zhou; Edward S X Moh; Richard Christopherson; Stephen J Clarke; Mark P Molloy; Nicolle H Packer
Journal:  J Proteomics       Date:  2014-05-17       Impact factor: 4.044

10.  Glycoproteomics-based identification of cancer biomarkers.

Authors:  Evelyn H Kim; David E Misek
Journal:  Int J Proteomics       Date:  2011-09-28
View more
  5 in total

1.  High expression of tissue O-linked glycans is associated with a malignant phenotype of cholangiocarcinoma.

Authors:  Krajang Talabnin; Chutima Talabnin; Juthamas Khiaowichit; Nuchanard Sutatum; Pundit Asavaritikrai; Sanong Suksaweang; Taweesak Tongtawee; Mayumi Ishihara; Parastoo Azadi; Banchob Sripa
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

2.  Globo H Is a Promising Theranostic Marker for Intrahepatic Cholangiocarcinoma.

Authors:  Tsai-Hsien Hung; Jung-Tung Hung; Chiao-En Wu; Yenlin Huang; Chien-Wei Lee; Chau-Ting Yeh; Yi-Hsiu Chung; Fei-Yun Lo; Li-Chun Lai; John K Tung; John Yu; Chun-Nan Yeh; Alice L Yu
Journal:  Hepatol Commun       Date:  2021-08-24

3.  Down-Regulation of C1GALT1 Enhances the Progression of Cholangiocarcinoma through Activation of AKT/ERK Signaling Pathways.

Authors:  Juthamas Khiaowichit; Chutima Talabnin; Chavaboon Dechsukhum; Atit Silsirivanit; Krajang Talabnin
Journal:  Life (Basel)       Date:  2022-01-25

4.  Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.

Authors:  Krajang Talabnin; Chutima Talabnin; Mayumi Ishihara; Parastoo Azadi
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

5.  Ganglioside GM2: a potential biomarker for cholangiocarcinoma.

Authors:  Krajang Talabnin; Chutima Talabnin; Tadahiro Kumagai; Nuchanard Sutatum; Juthamas Khiaowichit; Chawaboon Dechsukhum; Mayumi Ishihara; Parastoo Azadi; Banchob Sripa
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.